Okazaki N, Yoshino M, Yoshida T, Hizikata A, Hasegawa H
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1584-8.
One hundred and twenty-three patients with hepatocellular carcinoma and 4 patients with hepatoblastoma were treated with systemic chemotherapy, and then one patient with hepatocellular carcinoma and 4 patients with hepatoblastoma underwent hepatectomy. Preoperative chemotherapy was evaluated to have been successful in the patient with hepatocellular carcinoma and 3 of the 4 patients with hepatoblastoma. In the former, marked tumor necrosis was observed in the resected specimen. In the latter, a rapid decrease of serum AFP level (T1/2 was less than 13 days) was observed in the effective cases. Preoperative chemotherapy is very useful if effective drugs are available. However, the most serious problem in this field is the lack of drugs active against hepatocellular carcinoma. Our recent results of phase II studies on hepatocellular carcinoma using various drugs were as follows adriamycin 6% (1/17), tegafur 7% (1/15), UFT 4% (1/26) and VP-16 5% (1/21). Development of a new active anticancer agent is thought to be essential if treatment of hepatocellular carcinoma is to advance.
123例肝细胞癌患者和4例肝母细胞瘤患者接受了全身化疗，随后1例肝细胞癌患者和4例肝母细胞瘤患者接受了肝切除术。术前化疗被评估为在该例肝细胞癌患者以及4例肝母细胞瘤患者中的3例取得成功。在前者，切除标本中观察到明显的肿瘤坏死。在后者，有效病例中观察到血清甲胎蛋白水平迅速下降（半衰期小于13天）。如果有有效的药物，术前化疗非常有用。然而，该领域最严重的问题是缺乏对肝细胞癌有效的药物。我们最近使用各种药物对肝细胞癌进行的II期研究结果如下：阿霉素6%（1/17）、替加氟7%（1/15）、优福定4%（1/26）和依托泊苷5%（1/21）。如果肝细胞癌的治疗要取得进展，开发一种新的活性抗癌药物被认为是必不可少的。
